The current spread of multidrug-resistant malaria demands rapid vaccine development against the major pathogen Plasmodium falkiparum. The high quantities of protein required for a worldwide vaccination campaign select recombinant DNA technology as a practical approach for large-scale antigen production. We describe the vaccination of Aotus monkeys with two recombinant blood-stage antigens (recombinant p41 and 190N) that were considered as vaccine candidates because parasite-derived antigen preparations could protect susceptible monkeys from an otherwise lethal malaria infection. In contrast to the natural antigen, recombinant p41 protein (P. falciparum aldolase) could not protect monkeys, although all animals seroconverted. 190N antigen, a recombinant protein containing conserved sequences of the major merozoite surface antigen p190, protected two of five monkeys from critical levels ofinfection with the highly virulent FVO isolate of P. falckarum. However, the B-and T-cell responses to 190N antigen were similar in protected and unprotected animals so that other unknown factors may contribute to protection. Higher purity or lack of protective epitopes or different structure of protective epitopes in the recombinant proteins might explain the better performance of parasite-derived antigens in vaccination trials. The partial protection obtained with 190N antigen suggests that this molecule could contribute to a vaccine mixture against P. falciparum.
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The unicellular protozoan Plasmodium falciparum is the major pathogen causing lethal malaria in man. The sporozoite stage of the parasite is transmitted by the bite of a female Anopheles mosquito, invades the liver of the host, and develops into a mature schizont. Subsequent release of merozoites into the blood stream starts the infectious cycle, which ends with the manifestation of clinical malaria symptoms. Insecticide spraying briefly controlled the spread ofthe disease until resistant mosquito vectors developed. More recently, the worldwide spread of drug-resistant malaria has eliminated the hope of eradicating malaria by chemotherapy. The partial failure to control malaria by drugs explains the urgent necessity ofadditional means for malaria control, such as vaccines.
Successful experimental immunization trials with irradiated sporozoites (1) , blood-stage parasites (2), and later with purified parasite antigens (3) (4) (5) demonstrated that P. falciparum is vulnerable to immune attack in experimental infections. The major coat protein of merozoites referred to as pl90, gp195, or PSA (polymorphic schizont antigen) is a polymorphic glycoprotein with Mr between 190,000 and 205,000. Parasite-derived p190 and its processed products purified from parasite cultures could protect Aotus monkeys completely from malaria, and therefore, recommends it as a potential vaccine candidate (5) . Because of the problem of antigen polymorphism (6, 7) , two conserved regions of the p190 molecule (amino acid residues 146-312 and 1059-1196; ref. 8) were expressed in Escherichia coli as a single fusion protein termed 190N (9) . The use of strongly conserved regions of p190 reduces the risk of antigenic variation triggered by immunization. 190N antigen is recognized by sera of humans with acquired semiimmunity to malaria (9) and contains B-and T-cell epitopes (10). These properties made it an attractive subunit vaccine candidate based on the protective natural p190 molecule (9, 10) .
The other recombinant protein included in this study is a protein ofMr 41,000 (termed p41), which was identified as the aldolase of the parasite (4, 11) . The parasite-derived antigen preparation gave a marked degree of protection against malaria in immunized Saimiri monkeys (4) . Probably for functional reasons, the entire polypeptide sequence is highly conserved in all P. falciparum isolates analyzed (11) . The central function of aldolase for parasite metabolism makes it unlikely that mutants due to immunoselection will appear after immunization. Successful expression of the entire polypeptide in E. coli allowed us to vaccinate monkeys with the entire molecule (12) . The sequence of the recombinant antigen lacks only five amino acid residues present in the natural antigen. This lack does not affect the enzymatic or immunological features of the recombinant antigen, which are virtually identical to the natural protein (12 
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described (8, 12) . 190N antigen was further purified by an additional SDS/gel purification step followed by overnight dialysis and lyophilization. Both antigens and the control antigen (egg white lysozyme; Sigma) were dissolved in phosphate-buffered saline (PBS) at 700 ,ug/ml. The antigen preparation displayed a single band on SDS/polyacrylamide gels directly before immunization (data not shown).
Immunization. Antigen was injected at day-0, -21, and -42 of the experiment. At the same time the animals were bled for immunological assays. Each dose consisted of 350 gg of antigen dissolved in 500 p1L of PBS. Immediately before immunization the antigen solution was mixed with 500 ,ul of complete Freund's adjuvant for the first dose or with 500 ul of incomplete Freund's adjuvant for the booster injections. The sample was divided in four 250-pul aliquots and injected s.c. into four different spots on the back of each animal.
Parasites. Three P. falciparum isolates, FUP Palo Alto (Uganda), FCB-1 (Colombia), and FVO (Vietnam) previously adapted to Aotus monkeys were used. Parasite liquid nitrogen stocks were thawed and used directly to infect the monkeys.
Parasite Challenge. Fifteen days after the third immunization, all animals were challenged with 5 x 106 parasites of the FVO isolate of P. falciparum injected i.v. Parasitized erythrocytes (PRBC) were obtained from a monkey donor with exponential parasite growth. After challenge, the parasitemia was monitored daily independently by us and the Cali Malaria Centre by both thin and thick smears stained with Giemsa dye. Animals with 10% parasitemia were considered unprotected and immediately treated with Fansidar (HoffmannLaRoche). In one case (animal A17) Fansidar was given at 6.5% parasitemia to save the animal, which showed severe malaria symptoms.
Determination of Protein Concentration. Protein concentrations (antigen, PBRC) were determined colorimetrically by using a commercial protein assay (Bio-Rad) and the protocol supplied by the manufacturer (Bio-Rad, D-8000).
Analysis of Immune Response. Immune response in sera was maintained at day-0, after the first, second, and third immunizations, and, in addition, 5 or 10 days after parasite challenge. Antibody levels and specificities were determined by indirect immunofluorescence (IFA), ELISA, and immunoblotting.
IFA. IFA was accomplished by using serial dilutions of antisera in PBS and analyzed on multispot slide preparations of FCB-1 parasites fixed with acetone (4) . ELISA Assay. ELISA was done essentially as described by Perrin et al. (4) .
Immunoblot. Immunoblot analysis was performed as described (13). Each strip had one lane with a FCB-1 parasite lysate (30 ,ug of protein per lane) and two lanes with purified rp4l and 190N antigens (0.5 ,ug each). The monkey sera used were diluted 1/1000 in PBS. Antigen-antibody complexes were detected with 125I-labeled protein G (Amersham) followed by autoradiography. Rabbit serum to rp4l or 190N antigens (9, 11) was included as a positive control.
Lymphocyte Proliferation Assay. Peripheral blood mononuclear cells from each monkey were separated from heparinized blood obtained before the first and after the last immunization (day-42). Peripheral blood mononuclear cells were purified by Ficoll-Paque density gradient under the protocol of the supplier (Pharmacia). Cells were suspended at 5 x 106 cells per ml in RPMI 1640 medium (GIBCO) supplemented with 5% monkey B (-) serum, 2 mM L-glutamine, 25 mM Hepes, penicillin at 100 units/ml, and streptomycin at 100 ,ug/ml (GIBCO). Cells were cultured in triplicates of 200-,ul aliquots in 96-well microtiter plates (Nunc) with either a FCB-1 P. falciparum crude-antigen preparation (10 pug of protein per ml), an erythrocyte lysate (5 pug/ml), lysozyme at 5 tkg/ml, rp4l antigen at 5 tkg/ml, or 190N antigen at 5 ,ug/ml.
Control plates were stimulated with Con A at 10 Ag/ml (Difco). Plates were incubated for 6 days at 370C in 5% C02/95% air. Cells were pulse-labeled during the final 24 hr of culture with 1 puCi (1 Ci = 37 GBq) of tritiated methylthymidine (specific activity 2 Ci/mM, Amersham). Cultures were harvested onto glass-fiber filters by using an automated device, ( (11) . We asked whether inhibition of the enzymatic activity of p41 by antibodies contributes to protection. We therefore assayed aldolase activity in the presence of prechallenge sera of all experimental animals. As expected, only sera from the rp4l group could block the enzyme activity to the same degree as a rabbit control serum raised against parasite p41 (data not shown). A similar degree of aldolase inhibition was measured with sera from protected monkeys immunized with denatured or native parasite-derived aldolase (14).
We thus assumed the B-cell response determined in four independent assays to be sufficient for, at least, partial protection.
Cellular Immune Response. Lack of a correlation between protection and antibody titers in a previous and this trial suggested that other immune mechanisms, such as a cytotoxic T-cell response, could contribute to protection (4). We, therefore, measured T-cell stimulation in all experimental animals before immunization, after the second dose of antigen, and 10 days after parasite challenge (Fig. 1) . The preimmune stimulation index with either pure antigen or PRBC as antigen had background levels in all animals tested. Prechallenge Con A-induced T-cell proliferation varied extensively depending on the animal. Both recombinant antigens induced antigen-specific T-cell proliferation with rp4l, inducing significantly higher responses than 190N antigen ( Fig. 1) . PRBC antigen preparations stimulated T-cell proliferation in three of five rp4l-immunized animals, and the rest had background levels (Fig. 1 ). This result is probably related to the low amounts of specific antigen available for stimulation in parasite lysates. The T-cell stimulation index 10 days after the parasite challenge dropped significantly, even with Con A as stimulator-perhaps due to parasite invasion. after day-10 in nonprotected animals. Development of parasitemia in the control group and the animals immunized with rp41 was almost identical, although the mean parasitemia at day-9 was clearly lower than in the control group (Fig. 2) . At day-10 rapid parasite replication occurred in all animals ofthe rp4l group, which were rescued by chemotherapy. Because the results ofour vaccination trial deviate drastically from the result obtained with a natural p41 antigen preparation, we decided to repeat the experiment under the same conditions to exclude experimental errors. However, results were identical (data not shown).
Two of five animals in the group immunized with 190N antigen did not develop critical malaria symptoms; the peak parasitemia in these animals was 6% (D73) and 1.2% (F71). At day-20 these animals had completely cleared the parasites, and no blood-stage parasites were detected in the following 8 weeks. Another animal (B12) had a delayed onset of critical parasitemia. 190N antigen is thus significant as a p190-derived recombinant protein that partially protects Aotus monkeys from malaria.
DISCUSSION
We have tested two recombinant P. falciparum antigens (rp41 and 190N) as a malaria vaccine in the Aotus monkey animal model. The corresponding parasite-derived antigens protected previously immunized monkeys from malaria (3) (4) (5) . After immunization with the affinity-purified recombinant proteins, all animals seroconverted and developed similar parasite-specific antibody titers. The antibodies recognized their natural equivalent in the native (IFA, ELISA) or denatured conformation (immunoblot). In addition, both antigens induced antigen-specific T-cell proliferation. Furthermore, rp4l antibodies inhibit the aldolase activity to the same degree as in animals immunized with the natural protein (14) . Despite this parasite-specific humoral and cellular response, rp41 antigen did not protect monkeys, but 190N antigen induced partial malaria immunity.
190N antigen contains :209%o of the natural p190 protein sequence in an unnatural array, and thus epitopes required for complete protection could be either missing or in an adverse configuration. This interpretation would help explain why only two of five Aotus monkeys were protected against malaria infection. One protected animal (F71) had the highest titers of p190 antibodies in all assays and the lowest peak parasitemia (1.2%). However, another animal (D73) had clearly lower antibody levels, although it was protected (6%).
The T-cell response in the protected animals was similar to that of nonprotected monkeys (Fig. 1) . This result may suggest that sterile immunity requires stimulation of a yetunidentified subset of T cells by an epitope missing on 190N antigen but present on the natural p190 molecule. This explanation is consistent with the relatively poor stimulation obtained with PRBC as antigen.
Interpretation of the negative result obtained with rp4l, which contrasts with the result obtained with natural antigen, is more complicated (4) . The following differences could account for the different outcome of the two independent experiments: (i) rp4l antigen lacks the first five amino acids ofthe natural antigen due to attachment of an affinity sequence required for purification; this pentapeptide could form an important epitope.
(ii) We cannot exclude that the p41 antigen preparation used in the previous trial (4) contained minor but highly immunogenic contaminants that contributed to protection. This explanation is unlikely because prechallenge sera of protected animals immunoprecipitated only one major band of Mr 41,000 from parasite extracts (4).
(iii) The FVO isolate ofP. falciparum is more virulent than FUP Palo Alto, requiring early control of parasite attack. In Fig. 3 we compared postchallenge serum specificities of p41-protected and unprotected animals immunized with the recombinant antigen. It is evident that the animals immunized with natural p41 antigen and challenged with FUP Palo Alto detected several additional parasite antigens. This crossreactivity was missing in the sera of the monkeys immunized with rp4l antigen and challenged with FVO. We have shown above that a period of 20 days is sufficient for a primary immune response to the invading parasite. It is, therefore, difficult to determine whether the vaccine or the response against the other P.falciparum components protected against malaria in previous protection trials. 
